TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event

Kristian Reckzeh^{1

2

3}, Montserrat Estruch^{1

2}, Mina Ali^{2

3}, Alexandra Søgaard Helbo⁴, Anna Mosbech⁵, Kyoung Jae Won^{2

3}, Frank Rücker⁶, Konstanze Döhner⁶, Kim Theilgaard-Mönch^{1

2

3

7}

Affiliations

¹ The Finsen Laboratory, Rigshospitalet/National Univ. Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
² Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Novo Nordisk Foundation Centre for Stem Cell Biology, DanStem, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁴ Novo Nordisk Foundation, Copenhagen, Denmark.
⁵ Alk Abelló, Hørsholm, Denmark.
⁶ Department of Internal Medicine III, University Hospital of Ulm, University of Ulm, Ulm, Germany.
⁷ Department of Hematology, Rigshospitalet/National Univ. Hospital, University of Copenhagen, Copenhagen, Denmark.

Kristian Reckzeh et al. Br J Haematol. 2022 Apr.

. 2022 Apr;197(2):201-206.

doi: 10.1111/bjh.18027. Epub 2022 Feb 6.

¹ The Finsen Laboratory, Rigshospitalet/National Univ. Hospital, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
² Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Novo Nordisk Foundation Centre for Stem Cell Biology, DanStem, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁴ Novo Nordisk Foundation, Copenhagen, Denmark.
⁵ Alk Abelló, Hørsholm, Denmark.
⁶ Department of Internal Medicine III, University Hospital of Ulm, University of Ulm, Ulm, Germany.
⁷ Department of Hematology, Rigshospitalet/National Univ. Hospital, University of Copenhagen, Copenhagen, Denmark.

No abstract available

References

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-47.
1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Eng J Med. 2016;374:2209-21.
1. Delhommeau F, Dupont S, Valle VD, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Eng J Med. 2009;360:2289-301.
1. Lio C-WJ, Yuita H, Rao A. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. Blood. 2019;134:1487-97.
1. Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, et al. Loss of TET2in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015;29:910-22.